The Next Big Thing in Biotech: FDA Decisions
Senior columnist Adam Feuerstein says three big FDA drug approval decisions are the next big things to watch in biotech.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;
to send him an email.
